|Dr. Dewan Fazlul Hoque Chowdhury Ph.D.||Chairman, CEO & Pres||103.77k||N/A||1973|
|Mr. Justin Mclarney||Chief Fin. Officer||N/A||N/A||N/A|
|Mr. Bashir Timol||Chief Bus. Officer & Director||N/A||N/A||1974|
|Mr. Jay L. Warner||Head of U.S. Commercial Operations||N/A||N/A||N/A|
|Mr. Thomas Bendix Mortensen||Head of E.U. Commercial Operations & Marketing||N/A||N/A||N/A|
|Ms. Samantha Sanders||Global Head of Digital Programs||N/A||N/A||N/A|
Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. The company provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as for screening pre-diabetic patients. It has a license agreement with Healthimation, LLC, which licenses the company to make, have made, use, offer to sell, sell, and import intensive medical diabetes and weight management program for Type 2 diabetes, prediabetes, and general wellness; the Why WAIT app; and common law trademarks which incorporate the mark WHY WAIT or WHYWAIT and the use of licensed marks. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
Nemaura Medical Inc.’s ISS Governance QualityScore as of April 30, 2021 is 7. The pillar scores are Audit: 10; Board: 8; Shareholder Rights: 2; Compensation: 5.